|
?:authorAffiliation
|
-
[\'Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: david.rafael.martinez@gmail.com.\', \'Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.\', \'Duke Human Vaccine Institute, Duke University, Durham, NC, USA.\', \'Gilead Sciences, Inc., Foster City, CA, USA.\', \'Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.\', \'The Rockefeller University, New York, NY, USA; The Howard Hughes Medical Institute, Chevy Chase, MD, USA.\', \'Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: sheahan@email.unc.edu.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}